X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory <scp>ALL</scp>-Reference-Cited by-同舟云学术

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL

Published:2022-11-23 Issue:1 Volume:15 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Carlet Michela¹²,Schmelz Karin³⁴,Vergalli Jenny¹,Herold Tobias¹⁵⁶^ORCID,Senft Daniela¹^ORCID,Jurinovic Vindi¹⁵⁷,Hoffmann Thomas⁸^ORCID,Proba Jutta³,Weichert Nina³,Junghanß Christian⁹,Roth Mareike⁸,Eschenburg Georg¹⁰^ORCID,Barz Malwine¹¹^ORCID,Henze Günter³^ORCID,Eckert Cornelia³,Eggert Angelika³,Zuber Johannes⁸,Hundsdoerfer Patrick³¹²¹³,Jeremias Irmela¹⁶⁷^ORCID

Affiliation:

1. Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München German Center for Environmental Health (HMGU) Munich Germany

2. Department of Biotechnology and Food Engineering MCI, The Entrepreneur School Innsbruck Austria

3. Department of Pediatric Oncology/Hematology Charité‐Universitätsmedizin Berlin Germany

4. German Cancer Consortium (DKTK) Berlin Germany

5. Laboratory for Leukemia Diagnostics, Department of Medicine III University Hospital, LMU Munich Munich Germany

6. German Cancer Consortium (DKTK), Partnering Site Munich Munich Germany

7. Department of Pediatrics, Dr. von Hauner Children's Hospital University Hospital, LMU Munich Germany

8. Research Institute of Molecular Pathology (IMP) Vienna Austria

9. Department of Medicine, Clinic III – Hematology, Oncology, Palliative Medicine Rostock University Medical Center Rostock Germany

10. Department of Pediatric Surgery University Medical Center Hamburg‐Eppendorf Hamburg Germany

11. University Children's Hospital Zurich Zurich Switzerland

12. Berlin Institute of Health Berlin Germany

13. Department of Pediatrics Helios Klinikum Berlin‐Buch Berlin Germany

Funder

Alexander von Humboldt-Stiftung

Deutsche Forschungsgemeinschaft

Dr. Mildred Scheel Stiftung für Krebsforschung

H2020 European Research Council

Mehr LEBEN für Krebskranke Kinder – Bettina-Bräu-Stiftung

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.202114557

Reference92 articles.

1. TNFR2 is required for RIP1-dependent cell death in human leukemia

2. BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines

3. Design of Potent pan-IAP and Lys-Covalent XIAP Selective Inhibitors Using a Thermodynamics Driven Approach

4. Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy

5. IKKβ-mediated nuclear factor-κB activation attenuates smac mimetic–induced apoptosis in cancer cells

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential;Biomedicine & Pharmacotherapy;2024-06

2. (2,6-Dimethylphenyl)arsonic Acid Induces Apoptosis through the Mitochondrial Pathway, Downregulates XIAP, and Overcomes Multidrug Resistance to Cytostatic Drugs in Leukemia and Lymphoma Cells In Vitro;International Journal of Molecular Sciences;2024-04-26

3. Design, in silico evaluation, and in vitro verification of new bivalent Smac mimetics with pro-apoptotic activity;Methods;2024-04